Nature & Genes&Dev & EMBO J:肠癌背后的基因错误

2015-09-11 佚名 生物谷

随着肿瘤产生发展错误就会频频出现,而且每次一旦细胞分裂产生产生两个细胞,这些错误就会发生改变而且不断变得多样化;但在某些时候早期事件引发的癌症通常会被直接发现,就拿肠道癌来说,科学界在几乎30年来都认为是一种特殊的基因引发肠癌的发生。早在20世纪80年来来自英国癌症研究中心的科学家就发现了一种名为APC的腺瘤样息肉基因的错误拷贝,而且研究者在10例肠癌患者中就发现有8名患者携带APC的


随着肿瘤产生发展错误就会频频出现,而且每次一旦细胞分裂产生产生两个细胞,这些错误就会发生改变而且不断变得多样化;但在某些时候早期事件引发的癌症通常会被直接发现,就拿肠道癌来说,科学界在几乎30年来都认为是一种特殊的基因引发肠癌的发生。早在20世纪80年来来自英国癌症研究中心的科学家就发现了一种名为APC的腺瘤样息肉基因的错误拷贝,而且研究者在10例肠癌患者中就发现有8名患者携带APC的错误拷贝。

当APC错误在肠道内皮细胞中发生时就会引发接二连三的生长信号,从而促进细胞失控地复制,进而引发肠癌,而很多年来,研究者在多种疾病的研究中都肯定了APC错误的重要性。在正常的肠道细胞中,APC其中一项关键工作就是维持细胞中β连环蛋白的水平处于约束状态,一旦APC发生损伤,β连环蛋白水平就会增加,使得细胞暴露于多种生长信号中,从而细胞就会一直生长,这些信号被称为Wnt信号通路,其在肠癌的发病过程中扮演着重要角色。

肠道可以分为两部分—小肠组织和大肠组织,此前对小鼠进行研究发现,关闭肠道细胞中APC的功能就会引发小肠和大肠发生肿瘤。于是来自国外的研究人员就表示,为了观察是否APC的缺失会通过β连环蛋白来诱发肠癌,我们检测了是否工程化地含有错误的、活性版本β连环蛋白的细胞可以引发肿瘤。

研究者表示,我们在小鼠机体中测定了E-钙黏蛋白(E-cadherin)的水平,结果发现,相比小肠而言,大肠中的E-钙黏蛋白(E-cadherin)水平较高,而且E-钙黏蛋白(E-cadherin)的水平的增加的确可以帮助清理过多的β连环蛋白,从而抑制肠道中肿瘤的发生。β连环蛋白的错误在人类肠癌中并不常见,然而APC错误却在100例患者中的80例患者身上都会发生。

研究者David表示,是否改变E-钙黏蛋白的清理水平就可以帮助有效抑制肿瘤发生呢?研究者表示E-钙黏蛋白可以帮助有效抑制肠癌的发生。后期研究者们将进行更多深入的研究解析引发肠癌的分子机理,他们期望早日开发出治疗肠癌的新型个体化疗法。

原文出处:

The Cancer Genome Atlas Network.Comprehensive molecular characterization of human colon and rectal cancer. nature.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1982224, encodeId=ecc219822240a, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 21 00:11:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048682, encodeId=512f2048682e9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Aug 12 00:11:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59786, encodeId=a7ae59e86c5, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59787, encodeId=cc9e59e8758, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50448, encodeId=fae950448f8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:02:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880806, encodeId=2e411880806e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 09 09:11:00 CST 2016, time=2016-03-09, status=1, ipAttribution=)]
    2016-06-21 fzwish20000
  2. [GetPortalCommentsPageByObjectIdResponse(id=1982224, encodeId=ecc219822240a, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 21 00:11:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048682, encodeId=512f2048682e9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Aug 12 00:11:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59786, encodeId=a7ae59e86c5, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59787, encodeId=cc9e59e8758, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50448, encodeId=fae950448f8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:02:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880806, encodeId=2e411880806e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 09 09:11:00 CST 2016, time=2016-03-09, status=1, ipAttribution=)]
    2016-08-12 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1982224, encodeId=ecc219822240a, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 21 00:11:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048682, encodeId=512f2048682e9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Aug 12 00:11:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59786, encodeId=a7ae59e86c5, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59787, encodeId=cc9e59e8758, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50448, encodeId=fae950448f8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:02:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880806, encodeId=2e411880806e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 09 09:11:00 CST 2016, time=2016-03-09, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1982224, encodeId=ecc219822240a, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 21 00:11:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048682, encodeId=512f2048682e9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Aug 12 00:11:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59786, encodeId=a7ae59e86c5, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59787, encodeId=cc9e59e8758, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50448, encodeId=fae950448f8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:02:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880806, encodeId=2e411880806e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 09 09:11:00 CST 2016, time=2016-03-09, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1982224, encodeId=ecc219822240a, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 21 00:11:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048682, encodeId=512f2048682e9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Aug 12 00:11:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59786, encodeId=a7ae59e86c5, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59787, encodeId=cc9e59e8758, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50448, encodeId=fae950448f8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:02:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880806, encodeId=2e411880806e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 09 09:11:00 CST 2016, time=2016-03-09, status=1, ipAttribution=)]
    2015-12-30 xyfg98

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1982224, encodeId=ecc219822240a, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 21 00:11:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048682, encodeId=512f2048682e9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Aug 12 00:11:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59786, encodeId=a7ae59e86c5, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59787, encodeId=cc9e59e8758, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:54:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50448, encodeId=fae950448f8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:02:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880806, encodeId=2e411880806e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 09 09:11:00 CST 2016, time=2016-03-09, status=1, ipAttribution=)]
    2016-03-09 liye789132251

相关资讯

CSCO 2014:徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待

CONCUR研究是靶向药物瑞格非尼在亚太区,针对转移性结直肠癌(mCRC)患者进行的一项III期研究。 2012年,在全球进行的有关瑞格非尼对经治的mCRC患者疗效的研究——CORRECT研究,发表在《柳叶刀》The Lancet杂志上,这项研究报告的结果显示,瑞格非尼是能够在经所有标准治疗方案治疗后出现进展的结直肠癌患者中,首个显示出生存获益的小分子激酶抑制剂。瑞格非尼在欧洲和美国已经被批准用

Cell Rep:治疗肠癌的新型靶向疗法

近日,刊登在国际杂志Cell Reports上的一篇研究论文中,来自英国贝尔法斯特女王大学的研究人员揭示了他们在治疗肠癌患者疗法上的巨大进步。研究者表示,他们发现了两个引发肠癌细胞对疗法产生耐受性的机制,相关研究由英国癌症中心提供资助。 在之前的研究中研究者发现了两个名为MEK和MET的活性基因,这两个基因可以引发肠癌细胞对癌症疗法产生耐受性。van Schaeybroeck博士表示,当肠

CSCO 2014:青年医师论坛新辅助治疗专场: 紧扣主题、各有千秋

中山大学附属肿瘤医院、青年医师论坛新辅 助治疗专场、肠癌专 场策划负责人  陈功 本次CSCO年会上,CSCO青年医师论坛的安排可谓是独具匠心。光癌种就涉及了当前最常见的几大癌种——肠癌、胃癌、乳腺癌、肺癌,而另外还值得一提的是,这次新设了一个专场——新辅助治疗专场。 求同存异·新设新辅助治疗专场 现在,很多癌种在治疗上都有一定的共性,包括共有一些通路或靶点,或有相似的治疗模式

BMC Medicine:5种健康生活助你远离肠癌

近日研究发现,采用五个相结合的健康行为或可降低患肠癌的风险。德国波茨坦人类营养研究所的研究人员研究量化多个相结合的健康生活方式,观察这些生活方式对患肠癌风险的影响,他们发现这种影响对男性比女性要强。 Krasimira Aleksandrova表示:“这些数据给个人提供额外奖励,医疗专业机构和公共卫生当局为健康的生活方式行为投入资金。每个人可以贡献出很多方法以避免癌症的发生,如果健康的生活方

Chemistry &biology:局部荧光探针可以检测肠癌啦!

                                 &n

研究汇总:晚期肠癌靶向治疗进展

靶向药物的出现为晚期肠癌的治疗带来了新希望,在化疗方案基础上联合靶向药物可以进一步延长患者的生存期。目前已批准用于晚期肠癌的靶向药物包括:以血管内皮生长因子(vascular enclothelial growth factor,VEGF)为靶点的单克隆抗体,代表性药物是贝伐单抗,和以表皮生长因子受体(epide111lal growlh faclor receptor